Incyte Corporation

Hello, and welcome to the Insight second quarter earnings conference call and webcast. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer will follow the formal presentation. You may press star one at any time to be placed in the question queue. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Greg Scherzer, Investor Relations for Insight. Please go ahead, Greg.

Thank you, Kevin. Good morning and welcome to Insight's second quarter 2023 earnings conference call and webcast. The slides presented today are available for download on the investor section of our website. Joining me on the call today are Arve, Pablo, Barry, Stephen, and Christiana, who will deliver our prepared remarks and participate in the Q&A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements and are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our reports filed with the SEC. We will now begin the call with Hervé.

Thank you, Greg, and good morning, everyone. So we had another quarter of strong performance, with product revenues growing 25% year-over-year, driven by JakaFi, OpsiloR, and launches in Europe. ChakaFi net product revenue grew 14% compared to the second quarter of 2022. For Opselora, the growth trajectory continues with net product revenues in the second quarter of 80 million, driven by new patient flow and growth in refills. Additionally, the launch in Europe is underway and Opselora is now available to patients in Germany and Austria. Our other hematology and oncology net product revenues were 64 million for the quarter and up 30% year-over-year, driven by the growth of Pemazir and Minjuvi in ex-U.S. markets. Now turning to slide five, we continue to execute on our development efforts. Recently, we announced positive top-line results from two of our high-potential programs. The true AD3 study evaluating roxalitinib cream in pediatric atopic dermatitis and the Agave201 study evaluating axatelimab in chronic GVHD met their respective primary endpoints. Stephen will discuss this result in more detail during his prepared remark, as well as provide updates on the important progress we made across many of our high potential programs as shown at the bottom of the slide. We also strengthened our research and development organization by appointing Pablo Cagnoni as president and head of R&D, And in this position, and as member of the executive team, Pablo will lead Insights R&D activities. This new role aligns chemistry, biology, and early and late-stage clinical development with the goal of maximizing speed and productivity in our research and development efforts. I will now turn the call over to Pablo for a few words.